Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma

被引：0
|
作者：
Tsukada, Nobuhiro [1 ]
Ikeda, Masahiro [1 ]
Shingaki, Sumito [1 ]
Miyazaki, Kanji [1 ]
Meshitsuka, Sosuke [1 ]
Abe, Yu [1 ]
Yoshiki, Yumiko [1 ]
Suzuki, Kenshi [1 ]
机构：
[1] Japanese Red Cross Med Ctr, Div Hematol, Tokyo, Japan
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2014.11.313
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
270
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [21] THE QUADRUPLET COMBINATION OF CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE, AND DEXAMETHASONE IS SAFE AND WELL TOLERATED AS INDUCTION THERAPY FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MYELOMA PATIENTS
    Pawlyn, C.
    Davies, F.
    Cairns, D.
    Collett, C.
    Jones, J.
    Kaiser, M.
    Chalmers, A.
    Striha, A.
    Milligan, D.
    Lindsay, J.
    Chapman, C.
    Allotey, D.
    Shafeek, S.
    Karunanithi, K.
    Cook, G.
    Russell, N.
    Drayson, M.
    Owen, R.
    Gregory, W.
    Jackson, G.
    Morgan, G.
    HAEMATOLOGICA, 2015, 100 : 152 - 152
  • [22] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
    Mehra, Maneesha
    Cote, Sarah
    Kampfenkel, Tobias
    Nair, Sandhya
    BLOOD, 2019, 134
  • [23] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136 (08) : 936 - 945
  • [24] Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
    Rosinol, Laura
    Hebraud, Benjamin
    Oriol, Albert
    Colin, Anne-Laurene
    Tamayo, Rafael Rios
    Hulin, Cyrille
    Blanchard, Maria Jesus
    Caillot, Denis
    Sureda, Anna
    Hernandez, Miguel Teodoro
    Arnulf, Bertrand
    Mateos, Maria-Victoria
    Macro, Margaret
    San-Miguel, Jesus
    Belhadj, Karim
    Lahuerta, Juan Jose
    Garelik, M. Brigid
    Blade, Joan
    Moreau, Philippe
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah A.
    Anderson, Larry D., Jr.
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [26] The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    Nashimoto, Junichiro
    Uto, Yui
    Sato, Kota
    Miyazaki, Kanji
    Ogura, Mizuki
    Yoshiki, Yumiko
    Abe, Yu
    Tsukada, Nobuhiro
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 110 - 115
  • [27] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nishimura, Noriko
    Nagata, Yasuyuki
    Okazuka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 103 - 111
  • [28] Dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed multiple myeloma
    Kropff, Martin
    Liebisch, Peter
    Wand, Hannes
    Weisel, Katja
    Gann, Claudia-Nanette
    Knop, Stefan
    Einsele, Hermann
    BLOOD, 2007, 110 (11) : 1053A - 1053A
  • [29] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Kazuhito Suzuki
    Nobuhiro Tsukada
    Noriko Nishimura
    Yasuyuki Nagata
    Kiyoshi Okazuka
    Yuko Mishima
    Masahiro Yokoyama
    Kaichi Nishiwaki
    Tadao Ishida
    Shingo Yano
    Yasuhito Terui
    Kenshi Suzuki
    International Journal of Hematology, 2020, 111 : 103 - 111
  • [30] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Ajay K. Nooka
    Jonathan L. Kaufman
    Cesar Rodriguez
    Andrzej Jakubowiak
    Yvonne Efebera
    Brandi Reeves
    Tanya Wildes
    Sarah A. Holstein
    Larry D. Anderson
    Ashraf Badros
    Leyla Shune
    Ajai Chari
    Huiling Pei
    Annelore Cortoos
    Sharmila Patel
    J. Blake Bartlett
    Jessica Vermeulen
    Thomas S. Lin
    Paul G. Richardson
    Peter Voorhees
    Blood Cancer Journal, 12
12345